Reversible first-generation EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) have clinically improved prognosis in patients with non-small-cell lung cancer (NSCLC), medullary thyroid carcinoma, and breast cancer [19,20,21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.